Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pyrotinib Diarrhea Tolerance Study in HER2-positive Breast Cancer
NCT06362096Phase 2Not yet recruiting
- Start
- May 2024
- Primary completion
- May 2025
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
01
Overview
A Phase 2 trial of pyrotinib in HER2-positive breast cancer. Planned start May 2024; status: not yet recruiting.
02
Drugs
pyrotinib
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT06362096.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06362096.